Core Viewpoint - The company plans to utilize up to 500 million RMB of idle funds for cash management to enhance fund efficiency and increase returns [1][2] Group 1: Cash Management Proposal - The company and its subsidiaries will use a total of no more than 500 million RMB for cash management, investing in low-risk, high-liquidity financial products [1][2] - The primary goal is to activate idle funds without affecting daily operational cash flow and normal business activities [1][2] Group 2: Investment Guidelines - The investment will be limited to financial products issued by banks, fund companies, securities companies, and insurance companies, with a maximum investment period of 12 months [2] - The company will not invest in securities, unsecured bonds, domestic and foreign stocks, or any high-risk investment products [2] Group 3: Risk Management Measures - The finance department will continuously analyze and monitor the investment products, with the audit department and independent directors having oversight authority [3] - The investment strategy is based on principles of "standard operation, risk control, cautious investment, and value preservation," ensuring that daily operations and fund safety are prioritized [3] Group 4: Meeting and Documentation - The proposal was approved during the 18th meeting of the 10th Board of Directors, and relevant documents include the meeting resolution [4]
科华生物拟斥资5亿元闲置自有资金进行现金管理 投资低风险理财产品